Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06657053

Risk Factors of Epistaxis Recurrence in Adults

Facteurs De Risques De Récidive D'épistaxis Chez L'adulte

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
145 (estimated)
Sponsor
University Hospital, Grenoble · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

We study all patients admitted to the Emergency Department in the Institution between 01/2022 and 07/2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied. The relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test.

Detailed description

We study all patients admitted to the Emergency Department in the Institution between 01/2022 and 07/2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied : oral anticoagulants, sex, INR, anti-platelets drugs, diabetes, obesity, arterial hypertension, heart failure, hemoglobin at the admission, history of chronic rhinosinusitis, appointment with an ENT during the acute bleeding, sleep apnea, age, anatomic abnormality, recent surgery within 2 months, previous admission within 30 days in the emergency department, nasal trauma. The relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test. This study aim to provide a pronostic score of recurrence that can happen after the 3 fisrt weeks after the event. When a recurrence happens before 3 weeks, this was considered to be a non control of the bleeding episode. This score will be then tested on our cohort to evaluate specificity and sensibility.

Conditions

Timeline

Start date
2024-11-02
Primary completion
2025-03-01
Completion
2025-04-01
First posted
2024-10-24
Last updated
2024-10-24

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06657053. Inclusion in this directory is not an endorsement.